Allstate Corp Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Allstate Corp grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 103.0% during the 4th quarter, HoldingsChannel reports. The fund owned 7,664 shares of the biopharmaceutical company’s stock after buying an additional 3,889 shares during the period. Allstate Corp’s holdings in Regeneron Pharmaceuticals were worth $5,916,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. TD Private Client Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 15 shares in the last quarter. CYBER HORNET ETFs LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.0% during the fourth quarter. CYBER HORNET ETFs LLC now owns 301 shares of the biopharmaceutical company’s stock worth $232,000 after acquiring an additional 17 shares in the last quarter. Meyer Handelman Co. lifted its position in shares of Regeneron Pharmaceuticals by 0.6% during the fourth quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock worth $2,221,000 after acquiring an additional 18 shares in the last quarter. Gateway Investment Advisers LLC lifted its position in shares of Regeneron Pharmaceuticals by 4.3% during the fourth quarter. Gateway Investment Advisers LLC now owns 464 shares of the biopharmaceutical company’s stock worth $358,000 after acquiring an additional 19 shares in the last quarter. Finally, MGO One Seven LLC lifted its position in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. MGO One Seven LLC now owns 589 shares of the biopharmaceutical company’s stock worth $455,000 after acquiring an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Regeneron Pharmaceuticals Trading Down 0.7%

Shares of REGN stock opened at $634.62 on Wednesday. The business’s fifty day moving average is $727.07 and its 200 day moving average is $745.65. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market capitalization of $67.09 billion, a PE ratio of 15.46, a price-to-earnings-growth ratio of 1.41 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter last year, the business posted $8.22 earnings per share. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be given a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on REGN. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.